797 related articles for article (PubMed ID: 30187162)
1. Significance of CSF NfL and tau in ALS.
Schreiber S; Spotorno N; Schreiber F; Acosta-Cabronero J; Kaufmann J; Machts J; Debska-Vielhaber G; Garz C; Bittner D; Hensiek N; Dengler R; Petri S; Nestor PJ; Vielhaber S
J Neurol; 2018 Nov; 265(11):2633-2645. PubMed ID: 30187162
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis.
Grossman M; Elman L; McCluskey L; McMillan CT; Boller A; Powers J; Rascovsky K; Hu W; Shaw L; Irwin DJ; Lee VM; Trojanowski JQ
JAMA Neurol; 2014 Apr; 71(4):442-8. PubMed ID: 24492862
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.
Abu-Rumeileh S; Vacchiano V; Zenesini C; Polischi B; de Pasqua S; Fileccia E; Mammana A; Di Stasi V; Capellari S; Salvi F; Liguori R; Parchi P;
J Neurol; 2020 Jun; 267(6):1699-1708. PubMed ID: 32100123
[TBL] [Abstract][Full Text] [Related]
4. Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis.
Agnello L; Colletti T; Lo Sasso B; Vidali M; Spataro R; Gambino CM; Giglio RV; Piccoli T; Bivona G; La Bella V; Ciaccio M
Eur J Neurol; 2021 Jun; 28(6):1868-1875. PubMed ID: 33638255
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis.
Scarafino A; D'Errico E; Introna A; Fraddosio A; Distaso E; Tempesta I; Morea A; Mastronardi A; Leante R; Ruggieri M; Mastrapasqua M; Simone IL
J Neurol; 2018 Oct; 265(10):2353-2362. PubMed ID: 30116940
[TBL] [Abstract][Full Text] [Related]
6. Differential involvement of corticospinal tract (CST) fibers in UMN-predominant ALS patients with or without CST hyperintensity: A diffusion tensor tractography study.
Rajagopalan V; Pioro EP
Neuroimage Clin; 2017; 14():574-579. PubMed ID: 28337412
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.
Poesen K; De Schaepdryver M; Stubendorff B; Gille B; Muckova P; Wendler S; Prell T; Ringer TM; Rhode H; Stevens O; Claeys KG; Couwelier G; D'Hondt A; Lamaire N; Tilkin P; Van Reijen D; Gourmaud S; Fedtke N; Heiling B; Rumpel M; Rödiger A; Gunkel A; Witte OW; Paquet C; Vandenberghe R; Grosskreutz J; Van Damme P
Neurology; 2017 Jun; 88(24):2302-2309. PubMed ID: 28500227
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.
Gaiani A; Martinelli I; Bello L; Querin G; Puthenparampil M; Ruggero S; Toffanin E; Cagnin A; Briani C; Pegoraro E; Sorarù G
JAMA Neurol; 2017 May; 74(5):525-532. PubMed ID: 28264096
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease: A cross-sectional study.
Gagliardi D; Faravelli I; Meneri M; Saccomanno D; Govoni A; Magri F; Ricci G; Siciliano G; Pietro Comi G; Corti S
J Cell Mol Med; 2021 Apr; 25(8):3765-3771. PubMed ID: 33609080
[TBL] [Abstract][Full Text] [Related]
10. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
11. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
[TBL] [Abstract][Full Text] [Related]
13. Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease.
Llibre-Guerra JJ; Li Y; Schindler SE; Gordon BA; Fagan AM; Morris JC; Benzinger TLS; Hassenstab J; Wang G; Allegri R; Berman SB; Chhatwal J; Farlow MR; Holtzman DM; Jucker M; Levin J; Noble JM; Salloway S; Schofield P; Karch C; Fox NC; Xiong C; Bateman RJ; McDade E
JAMA Netw Open; 2019 Dec; 2(12):e1917126. PubMed ID: 31825500
[TBL] [Abstract][Full Text] [Related]
14. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients.
Steinacker P; Feneberg E; Weishaupt J; Brettschneider J; Tumani H; Andersen PM; von Arnim CA; Böhm S; Kassubek J; Kubisch C; Lulé D; Müller HP; Muche R; Pinkhardt E; Oeckl P; Rosenbohm A; Anderl-Straub S; Volk AE; Weydt P; Ludolph AC; Otto M
J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):12-20. PubMed ID: 26296871
[TBL] [Abstract][Full Text] [Related]
15. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
Lu CH; Macdonald-Wallis C; Gray E; Pearce N; Petzold A; Norgren N; Giovannoni G; Fratta P; Sidle K; Fish M; Orrell R; Howard R; Talbot K; Greensmith L; Kuhle J; Turner MR; Malaspina A
Neurology; 2015 Jun; 84(22):2247-57. PubMed ID: 25934855
[TBL] [Abstract][Full Text] [Related]
16. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.
Illán-Gala I; Alcolea D; Montal V; Dols-Icardo O; Muñoz L; de Luna N; Turón-Sans J; Cortés-Vicente E; Sánchez-Saudinós MB; Subirana A; Sala I; Blesa R; Clarimón J; Fortea J; Rojas-García R; Lleó A
Neurology; 2018 Oct; 91(17):e1619-e1628. PubMed ID: 30291183
[TBL] [Abstract][Full Text] [Related]
17. Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS.
Kasai T; Kojima Y; Ohmichi T; Tatebe H; Tsuji Y; Noto YI; Kitani-Morii F; Shinomoto M; Allsop D; Mizuno T; Tokuda T
Ann Clin Transl Neurol; 2019 Dec; 6(12):2489-2502. PubMed ID: 31742901
[TBL] [Abstract][Full Text] [Related]
18. Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid.
Petrozziello T; Amaral AC; Dujardin S; Farhan SMK; Chan J; Trombetta BA; Kivisäkk P; Mills AN; Bordt EA; Kim SE; Dooley PM; Commins C; Connors TR; Oakley DH; Ghosal A; Gomez-Isla T; Hyman BT; Arnold SE; Spires-Jones T; Cudkowicz ME; Berry JD; Sadri-Vakili G
Brain Pathol; 2022 Mar; 32(2):e13035. PubMed ID: 34779076
[TBL] [Abstract][Full Text] [Related]
19. CSF glial markers correlate with survival in amyotrophic lateral sclerosis.
Süssmuth SD; Sperfeld AD; Hinz A; Brettschneider J; Endruhn S; Ludolph AC; Tumani H
Neurology; 2010 Mar; 74(12):982-7. PubMed ID: 20308682
[TBL] [Abstract][Full Text] [Related]
20. Hyperintensity of the corticospinal tract on FLAIR: A simple and sensitive objective upper motor neuron degeneration marker in clinically verified amyotrophic lateral sclerosis.
Jin J; Hu F; Zhang Q; Jia R; Dang J
J Neurol Sci; 2016 Aug; 367():177-83. PubMed ID: 27423585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
